Skip to main content

Table 1 Summary of WHO recommended first-line antiretroviral regimens for children and adolescents[2]

From: Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol

  Children 3 years to less than 10 years and adolescents <35 kg Adolescents (10 to 19 years) ≥35 kg
Preferred ABCa + 3TC + EFV TDF + 3TC (or FTC) + EFVa
Alternatives ABC + 3TC + NVP  
  AZT + 3TC + EFV AZT + 3TC + EFV
  AZT + 3TC + NVP AZT + 3TC + NVP
  TDF + 3TC (or FTC) + EFV TDF + 3TC (or FTC) + NVP
  TDF + 3TC (or FTC) + NVP  
Special circumstancesc d4Tb + 3TC + EFV ABC + 3TC + EFV
d4Tb + 3TC + NVP ABC + 3TC + NVP
  1. aThese recommendations apply to children and adolescents who are initiating first-line antiretroviral therapy; bd4T use should be restricted to situations in which toxicity to AZT is suspected or confirmed and access to ABC or TDF is lacking.
  2. cSpecial circumstances may include situations where preferred or alternative regimens may not be available or suitable because of significant toxicities, anticipated drug-drug interactions, drug procurement and supply management issues, or for other reasons.
  3. 3TC lamivudine, ABC abacavir, AZT zidovudine, d4T stavudine, EFV efavirenz, FTC emtricitabine, LPV/r lopinavir/ritonavir, NVP nevirapine, TDF tenofovir, WHO World Health Organization.